Beyond Genetic Enhancement: The Enhanced Steatosis Index Demands Risk-Stratified Thresholds and Subgroup-Specific Solutions [0.03%]
遗传增强之外：改良型脂肪变指数要求风险分层阈值和亚组特异性解决方案
Jiajing Zhao,Liping Liu
Jiajing Zhao
Response to Letter to the Editor Regarding 'Considerations on MRI-Based Stratification for Retreatment After TACE in HCC' [0.03%]
关于“基于MRI分层经TACE治疗后肝癌再治考虑”的来信回复
Weilang Wang,Yuan-Cheng Wang
Weilang Wang
Pingfeng Wang,Xiaoyu Chen,Yanjin Song
Pingfeng Wang
Quality of Life in Patients With Variant Syndromes of Autoimmune Liver Diseases-A Cross-Sectional Multicentre Study [0.03%]
自身免疫性肝病变异综合征患者的生存质量——一项多中心横断面研究
Natalie Uhlenbusch,Romée J A L M Snijders,Meike Mund et al.
Natalie Uhlenbusch et al.
Background & aims: Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) go along with reduced health-related quality of life (HRQOL). Variant syndromes, that is, condition...
TNF-α Inhibitors and HBV Reactivation Risk in HBsAg-/Anti-HBc+ Patients: A Systematic Review and Meta-Analysis [0.03%]
乙型肝炎表面抗原阴性_intermeddash;乙型肝炎核心抗体阳性患者使用肿瘤坏死因子-α抑制剂后发生乙肝再激活的风险：系统评价和 meta 分析
Meng Hsuan Kuo,Ping-Hung Ko,Chen-Chou Lee et al.
Meng Hsuan Kuo et al.
Background: Tumour necrosis factor-α (TNF-α) inhibitors are integral in the treatment of immune-mediated inflammatory diseases but may precipitate hepatitis B virus reactivation (HBVr) in HBsAg-/anti-HBc+ patients. APAS...
Comment on 'Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice' [0.03%]
关于“Mtarc1丢失能够保护小鼠对抗脂肪性肝病”的评论
Baodong Wang,Jiayuan Huang,Zhiyun Chen
Baodong Wang
Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol-Associated Liver Disease [0.03%]
酒精性肝病患者不良肝脏事件和不良心脏事件的性别差异
Pojsakorn Danpanichkul,Donghee Kim,Karn Wijarnpreecha et al.
Pojsakorn Danpanichkul et al.
Excluding Ascites From the GEMA-Na Score Does Not Impact Outcome Predictions in Liver Transplant Candidates [0.03%]
排除腹水对肝脏移植候选人的GEMA-Na评分预后预测没有影响
Manuel Luis Rodríguez-Perálvarez,Antonio Manuel Gómez-Orellana,Avik Majumdar et al.
Manuel Luis Rodríguez-Perálvarez et al.
Background and aims: Although GEMA-Na outperforms MELD 3.0 for liver allocation, concerns about the subjectivity of its ascites component persist. We compared the performance of a GEMA-Na iteration that excludes ascites w...
Reply to Reconsidering the Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes [0.03%]
脂肪肝疾病对不良妊娠结局影响的再思考——回信
Hui Wang,Lei Yang,Yan Long
Hui Wang
Efficacy, Safety and Tolerability of Volixibat, an IBAT Inhibitor, in Patients With Intrahepatic Cholestasis of Pregnancy [0.03%]
用于妊娠期肝内胆汁淤积症患者的IBAT抑制剂Volixibat疗效、安全性和耐受性的研究
Caroline Ovadia,Sophia Stone,Baha Sibai et al.
Caroline Ovadia et al.
Intrahepatic cholestasis of pregnancy (ICP) presents with cholestatic pruritus, elevated sBA and increased risk of adverse perinatal outcomes. Volixibat is a minimally absorbed IBAT inhibitor that interrupts enterohepatic recirculation. We ...